Welcome
Support Centre
29 August 2014 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   news
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes
statistics

[ Print-friendly version ]
Effectiveness of the psychological and pharmacological treatment of catastrophisation in patients with fibromyalgia: a controlled randomised trial
ISRCTN ISRCTN10804772
DOI 10.1186/ISRCTN10804772
ClinicalTrials.gov identifier
EudraCT number
Public title Effectiveness of the psychological and pharmacological treatment of catastrophisation in patients with fibromyalgia: a controlled randomised trial
Scientific title
Acronym N/A
Serial number at source ETES nº PI07/90959
Study hypothesis Pharmacological and psychological treatments are more effective for the treatment of pain catastrophising in patients with fibromyalgia than usual treatment at primary care level.
Lay summary
Ethics approval Ethics approval received from the Ethical Review Board of the Regional Health Authority in February 2007 (ref: ETES nº PI07/90959).
Study design Multicentre three-arm random allocation controlled trial
Countries of recruitment Spain
Disease/condition/study domain Fibromyalgia
Participants - inclusion criteria 1. Aged 18 - 65 years, either sex
2. Able to understand and read Spanish
3. Fulfil criteria for primary fibromyalgia according to the American College of Rheumatology
4. No previous psychological treatment
5. No pharmacological treatment or acceptance to discontinue it two weeks before the onset of the study
6. Signed informed consent
Participants - exclusion criteria 1. Severe Axis I psychiatric disorder (dementia, schizophrenia, paranoid disorder, abuse of alcohol and/or drug disorders)
2. Severe Axis II disorder from the clinician viewpoint that prevents the patient from following the treatment protocol
3. Pregnancy or lactation
4. Refusal to participate
Anticipated start date 01/09/2008
Anticipated end date 31/12/2009
Status of trial Completed
Patient information material Not available in web format, please use the contact details below to request a patient information sheet
Target number of participants 180 patients (60 in each of the three groups)
Interventions Psychological intervention:
Manualised protocol developed by Prof. Escobar et al, of the University of New Jersey, for the treatment of somatoform disorders that has been adapted by our group for the treatment of fibromyalgia. It includes 10 weekly sessions of cognitive-behaviour therapy.

Pharmacological intervention:
In this group of patients, pregabalin (300 - 450 mg/day), recommended for the treatment of fibromyalgia, associated with duloxetine (60 - 120 mg/day) if there is comorbid depression, will be administered.

Treatment as usual at primary care level:
This group will follow the usual treatment given at primary care level.
Primary outcome measure(s) The major outcome is pain catastrophising in patients with fibromyalgia. This construct will be assessed with the Spanish version of the Pain Catastrophising Scale. Assessments will take place at baseline, 3 months, 6 months and 1-year post-intervention
Secondary outcome measure(s) 1. The following socio-demographic data will be collected: sex, age, marital status, education, occupation and social class: administered only at baseline
2. The diagnosis of psychiatric disorders will be made with the Structured Polyvalent Psychiatric Interview, a psychiatric interview extensively used for the study of somatoform disorders: administered only at baseline
3. Hamilton test for Anxiety (HAM-A) and for Depression (HAM-D); assessments will take place at baseline, 3 months, 6 months and 1-year post-intervention
4. Fibromyalgia Impact Questionnaire (FIQ): the FIQ is a 10-item self-report questionnaire developed to measure the health status of fibromyalgia patients; assessments will take place at baseline, 3 months, 6 months and 1-year post-intervention
Sources of funding The Carlos III Health Institute (Instituto de Salud Carlos III) (Spain) (ref: ETES nº PI07/90959)
Trial website
Publications 2009 protocol in http://www.ncbi.nlm.nih.gov/pubmed/19389246
Contact name Dr  Javier  Garcia-Campayo
  Address Servicio de Psiquiatría
Hospital Universitario Miguel Servet
Avda Isabel La Católica 1
  City/town Zaragoza
  Zip/Postcode 50009
  Country Spain
  Tel +34 (0)976 25 36 21
  Fax +34 (0)976 25 40 06
  Email jgarcamp@arrakis.es
Sponsor The Carlos III Health Institute (Instituto de Salud Carlos III) (Spain)
  Address C/ Sinesio Delgado 6
  City/town Madrid
  Zip/Postcode 28029
  Country Spain
  Tel +34 (0)91 82 22 131
  Fax +34 (0)91 38 77 789
  Email oficina.informacion@isciii.es
  Sponsor website: http://www.isciii.es
Date applied 11/06/2008
Last edited 20/07/2009
Date ISRCTN assigned 29/09/2008
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2014 ISRCTN unless otherwise stated.